Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
SYDNEY, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 7-11, 2018, in Washington, D.C.
Abstract titles and authors are: Title: Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
Authors: Victoria Atkinson; Frederic Triebel; Christian Mueller; Chrystelle Brignone; Melissa Eastgate; Amitesh Roy; Adnan Khattak; Andrew Haydon
Title: A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractory NSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination with Pembrolizumab (TACTI-002)
Authors: Martin Forster; Frederic Triebel; Christian Mueller; Chrystelle Brignone; Tatsiana Skrahina
The exact time of Immutep’s presentation and further details will be available closer to the conference date.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Further information can be found on the Company’s website www.immutep.com or by contacting:
U.S. Investors:Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited+1 (917) 860-9404; firstname.lastname@example.org
Garth Russell, LifeSci Advisors +1 (646) 876-3613; email@example.com
Australian Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2 8234 0105; firstname.lastname@example.org